Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases

Cell cycle regulators, such as the CDC25 phosphatases, are potential targets for the development of new anticancer drugs. Here we report the identification and the characterization of BN82685, a quinone-based CDC25 inhibitor that is active in vitro and in vivo. BN82685 inhibits recombinant CDC25A, B, and C phosphatases in vitro. It inhibits the growth of human tumor cell lines with an IC50 in the submicromolar range, independently of their resistance to chemotherapeutic agents. This inhibitory effect is irreversible on both the purified CDC25 enzyme in vitro and on tumor cell proliferation. The specificity of BN82685 towards the CDC25 phosphatases is shown by an increase in cyclin-dependent kinase 1 tyrosine 15 phosphorylation, by the reversion of the mitosis-inducing effect of CDC25B overexpression in HeLa cells, and by the lack of a growth inhibitory effect in an assay based on the use of a CDC25-independent fission yeast model. Finally, when administered p.o., BN82685 is shown to inhibit the growth of the human pancreatic tumor Mia PaCa-2 xenografted in athymic nude mice. BN82685 is therefore a promising new compound targeting CDC25, which confirms the interest of the inhibition of these enzymes as an anticancer therapeutic strategy.

[1]  P. Vaglio,et al.  Functional cdc25C dual-specificity phosphatase is required for S-phase entry in human cells. , 2003, Molecular biology of the cell.

[2]  M. Ranson,et al.  DT-diaphorase: a target for new anticancer drugs. , 2004, Cancer treatment reviews.

[3]  É. Oswald,et al.  The bacterial cytolethal distending toxin (CDT) triggers a G2 cell cycle checkpoint in mammalian cells without preliminary induction of DNA strand breaks , 1999, Oncogene.

[4]  J. Rudolph,et al.  Cdc25 phosphatases and cancer. , 2004, Chemistry & biology.

[5]  M. Montenarh,et al.  An additional transcript of the cdc25C gene from A431 cells encodes a functional protein. , 2000, International journal of oncology.

[6]  J. Noordhoek,et al.  Quinone toxicity in DT-diaphorase-efficient and -deficient colon carcinoma cell lines. , 1999, Biochemical pharmacology.

[7]  N. Mailand,et al.  Centrosome-associated Chk1 prevents premature activation of cyclin-B–Cdk1 kinase , 2004, Nature Cell Biology.

[8]  Bernard Ducommun,et al.  Inhibitors of the CDC25 phosphatases. , 2003, Progress in cell cycle research.

[9]  M. Pirrung,et al.  Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones. , 2003, Journal of medicinal chemistry.

[10]  M. Tsai,et al.  Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer , 2003, Oncogene.

[11]  B. Ducommun,et al.  Human CDC25B and CDC25C differ by their ability to restore a functional checkpoint response after gene replacement in fission yeast. , 2002, Biochemical and biophysical research communications.

[12]  V. Baldin,et al.  A novel synthetic inhibitor of CDC25 phosphatases: BN82002. , 2004, Cancer research.

[13]  N. Hayward,et al.  Multiple splicing variants of cdc25B regulate G2/M progression. , 1999, Biochemical and biophysical research communications.

[14]  A. Senderowicz.  Targeting cell cycle and apoptosis for the treatment of human malignancies. , 2004, Current opinion in cell biology.

[15]  H. Friess,et al.  Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma , 2004, Oncogene.

[16]  I. Hoffmann,et al.  Cell cycle regulation by the Cdc25 phosphatase family. , 2000, Progress in cell cycle research.

[17]  Ivet Bahar,et al.  Discovery and Characterization of Novel Small Molecule Inhibitors of Human Cdc25B Dual Specificity Phosphatase , 2004, Molecular Pharmacology.

[18]  B. Monsarrat,et al.  Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the G2–M transition , 2004, Journal of Cell Science.

[19]  Ingrid Hoffmann,et al.  Cdc25b and Cdc25c Differ Markedly in Their Properties as Initiators of Mitosis , 1999, The Journal of cell biology.

[20]  B. Ducommun,et al.  Ability of human CDC25B phosphatase splice variants to replace the function of the fission yeast Cdc25 cell cycle regulator. , 2004, FEMS yeast research.

[21]  G. Superti-Furga,et al.  Alternative splicing of the human CDC25B tyrosine phosphatase. Possible implications for growth control? , 1997, Oncogene.

[22]  S. Tsai,et al.  Cdc25B Functions as a Novel Coactivator for the Steroid Receptors , 2001, Molecular and Cellular Biology.

[23]  P. Wipf,et al.  Synthesis and biological evaluation of caulibugulones A-E. , 2004, Organic & biomolecular chemistry.

[24]  C. Fisher,et al.  Antisense phosphorothioate oligonucleotides specifically down‐regulate cdc25B causing S‐phase delay and persistent antiproliferative effects , 1998, International journal of cancer.

[25]  B. Ducommun,et al.  A fission yeast strain expressing human CDC25A phosphatase: a tool for selectivity studies of pharmacological inhibitors of CDC25 , 2004, Current Genetics.

[26]  B. Ducommun,et al.  Evolutionary Conservation of a Novel Splice Variant of the Cds1/CHK2 Checkpoint Kinase Restricted to its Regulatory Domain , 2004, Cell cycle.

[27]  L. Busino,et al.  Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis , 2004, Oncogene.

[28]  H. Schaller,et al.  Alternative splicing in the regulatory region of the human phosphatases CDC25A and CDC25C. , 2000, European journal of cell biology.

[29]  C. Ryu,et al.  5-Arylamino-2-methyl-4,7-dioxobenzothiazoles as inhibitors of cyclin-dependent kinase 4 and cytotoxic agents. , 2000, Bioorganic & medicinal chemistry letters.